ATE235238T1 - Verwendung von 2,3- alkylcaebonyloxybenzoesäure zur behandlung des atemunwohlseinsydroms bei erwachsenen - Google Patents

Verwendung von 2,3- alkylcaebonyloxybenzoesäure zur behandlung des atemunwohlseinsydroms bei erwachsenen

Info

Publication number
ATE235238T1
ATE235238T1 AT95944240T AT95944240T ATE235238T1 AT E235238 T1 ATE235238 T1 AT E235238T1 AT 95944240 T AT95944240 T AT 95944240T AT 95944240 T AT95944240 T AT 95944240T AT E235238 T1 ATE235238 T1 AT E235238T1
Authority
AT
Austria
Prior art keywords
acid
alkylcaebonyloxybenzoic
sydrome
unawareness
adults
Prior art date
Application number
AT95944240T
Other languages
English (en)
Inventor
Michael T Flavin
Deanna J Nelson
Julian F Borgia
Gary J Jesmok
Original Assignee
Advanced Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Life Sciences Inc filed Critical Advanced Life Sciences Inc
Application granted granted Critical
Publication of ATE235238T1 publication Critical patent/ATE235238T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95944240T 1994-12-30 1995-12-21 Verwendung von 2,3- alkylcaebonyloxybenzoesäure zur behandlung des atemunwohlseinsydroms bei erwachsenen ATE235238T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/366,885 US5504111A (en) 1994-12-30 1994-12-30 Use of 2,3 alkylcarbonyloxybenzoic acid in treating adult respiratory distress syndrome
PCT/US1995/016892 WO1996020702A1 (en) 1994-12-30 1995-12-21 The use of 2,3-alkylcarbonyloxybenzoic acid in treating adult respiratory distress syndrome

Publications (1)

Publication Number Publication Date
ATE235238T1 true ATE235238T1 (de) 2003-04-15

Family

ID=23444992

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02009331T ATE337789T1 (de) 1994-12-30 1995-12-21 Pharmazeutische zusammensetzung enthaltend 2,3- alkylcarbonyloxybenzoesäure und ibuprofen
AT95944240T ATE235238T1 (de) 1994-12-30 1995-12-21 Verwendung von 2,3- alkylcaebonyloxybenzoesäure zur behandlung des atemunwohlseinsydroms bei erwachsenen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02009331T ATE337789T1 (de) 1994-12-30 1995-12-21 Pharmazeutische zusammensetzung enthaltend 2,3- alkylcarbonyloxybenzoesäure und ibuprofen

Country Status (7)

Country Link
US (1) US5504111A (de)
EP (2) EP0801563B1 (de)
JP (1) JPH10511953A (de)
AT (2) ATE337789T1 (de)
AU (1) AU4609096A (de)
DE (2) DE69535210T2 (de)
WO (1) WO1996020702A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955496A (en) * 1996-08-13 1999-09-21 The Regents Of The University Of California Dihydroxy-oxy-eicosadienoates
US6174695B1 (en) 1997-08-12 2001-01-16 The Regents Of The University Of California Epoxide hydrolase inhibitor methods
WO2004032825A2 (en) * 2001-11-02 2004-04-22 Advanced Life Sciences, Inc. Use of 2,3 alkylcarbonyloxybenzoic acids in the treatment of anthrax
EP1539132A4 (de) * 2002-07-25 2007-10-31 Advanced Life Sciences Inc Verwendung von 2,3 alkylcarbonyloxybenzosäuren, ihre derivate und analoga bei der behandlung von gewebe- und zellfunktionsschäden und verletzungen in säugetieren

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443476A (en) * 1981-07-20 1984-04-17 The Upjohn Company Treatment of adult respiratory distress syndrome
DE3270988D1 (en) * 1981-07-20 1986-06-12 Upjohn Co Use of ibuprofen or flurbiprofen for the manufacture of a medicament for treating respiratory disorders
US4447451A (en) * 1981-07-20 1984-05-08 The Upjohn Manufacturing Company M Treatment of adult respiratory distress syndrome
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US4703040A (en) * 1985-04-03 1987-10-27 Markov Angel K Treatment of adult respiratory distress syndrome (ARDS) using fructose diphosphate (FDP)
US5198420A (en) * 1989-10-02 1993-03-30 The General Hospital Corporation Use of mullerian inhibiting substance and its agonists and antagonists in the treatment of respiratory distress syndrome
IE911697A1 (en) * 1990-05-24 1991-12-04 Zeneca Ltd Therapeutic agent
JP2925391B2 (ja) * 1992-01-09 1999-07-28 サントリー株式会社 Ａｒｄｓ治療用医薬組成物
US5389522A (en) * 1993-03-19 1995-02-14 Repine; John E. Serum antioxidants as predictors of the adult respiratory distress syndrome in septic patients

Also Published As

Publication number Publication date
EP1226821B1 (de) 2006-08-30
DE69530120T2 (de) 2004-02-05
AU4609096A (en) 1996-07-24
JPH10511953A (ja) 1998-11-17
EP0801563A1 (de) 1997-10-22
US5504111A (en) 1996-04-02
DE69530120D1 (de) 2003-04-30
EP0801563B1 (de) 2003-03-26
ATE337789T1 (de) 2006-09-15
EP1226821A2 (de) 2002-07-31
DE69535210T2 (de) 2007-08-02
EP1226821A3 (de) 2003-09-17
WO1996020702A1 (en) 1996-07-11
DE69535210D1 (de) 2006-10-12

Similar Documents

Publication Publication Date Title
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE3878866T2 (de) 3-indolpyruvsaeure-derivate und deren verwendung als arznemittel.
ATE100325T1 (de) Verwendung von milch zur herstellung einer hyperimmunmilchverbindung zur behandlung von erkrankungen des atmungssystems bei saeugetieren.
ATE110265T1 (de) Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums.
ATE71843T1 (de) Behandlung des atemunwohlseinsyndroms bei erwachsenen.
ES2039943T3 (es) Procedimiento y aparato para la purificacion de agua empleando polipirrolidona.
EP0363415A4 (en) Compounds for the treatment of alzheimer's disease
DE69214467T3 (de) Verwendung von L-2-oxo Thiazolidin-4-carboxylat zur Behandlung von Atemnotsyndrom
GR3025488T3 (en) Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions
PL335134A1 (en) Novel pharmaceutic compositions useful in treating ards and trds
ATE185973T1 (de) Verwendung von humanem atrio-natriuretischem peptid zur herstellung eines medikaments zur behandlung des atemunwohlseinsyndroms bei erwachsenen
DE69721120D1 (de) Verwendung von menschlichen Chemokin beta-9 zur Behandlung von Atemnotsyndrom bei Erwachsenen
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE69424009T2 (de) Verwendung von (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidinacetamid zur Herstellung eines Medikaments zur Behandlung von Angst
ATE166881T1 (de) Verfahren zur herstellung von faktor viii
ATE235238T1 (de) Verwendung von 2,3- alkylcaebonyloxybenzoesäure zur behandlung des atemunwohlseinsydroms bei erwachsenen
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
DE69431199T2 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
DE3885818D1 (de) Trinatriumsalz des 2,4,6-Trimercapto-s-triazin-nonahydrats und Verfahren zur Herstellung.
FI954138A0 (fi) Hydroksimetyylifuratsaanikarboksyylihappojohdannaiset ja niiden käyttö sydänverisuonitautien käsittelyssä
ATE244008T1 (de) Verwendung von makroliden zur behandlung von akuten lungenverletzungen
DE69006037D1 (de) Aus L-Asparagine- oder L-Glutaminesäure abgeleiteter Süsstoff und Verfahren zur Herstellung.
AU560542B2 (en) Pyridazine derivatives which have c.n.s. activity
ATE209005T1 (de) Verwendung von threonin zur behandlung der phenylketonurie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties